Drugs / GNR-068
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06481215 | Mar → Sep 2022 | — | AO GENERIUM | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06488664 | Jul 2023 → Apr 2025 | psoriasis | AO GENERIUM | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GNR-068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06488664 ↗ |
| Known as | ustekinumab | “GNR-068 (ustekinumab) is being developed as a biosimilar to the drug Stelara®” NCT06481215 ↗ |
| Route | Subcutaneous | “GNR-068 was administered subcutaneously” NCT06488664 ↗ |